The vaccine's created from one tumor sample per the trial design. Adjuvants and neoadjuvants will increase efficacy as we see from newer trials. It would be very intrusive to have a second surgical resection for rGBM patients so I do not believe clinicians will want to do that given the already excellent cure rates we see for those patients.
Market Data 
Markets 
AI
